Cowen assumed coverage on shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) in a research report report published on Thursday morning, TipRanks reports. The brokerage issued a buy rating and a $48.00 price objective on the stock.
Separately, Royal Bank of Canada reaffirmed an outperform rating on shares of Roche Holdings AG Basel in a report on Monday, December 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. Roche Holdings AG Basel has a consensus rating of Buy and a consensus target price of $42.50.
RHHBY stock opened at $41.20 on Thursday. The firm has a market capitalization of $290.31 billion, a PE ratio of 17.76, a PEG ratio of 2.49 and a beta of 0.50. Roche Holdings AG Basel has a twelve month low of $31.81 and a twelve month high of $42.88. The stock has a 50-day simple moving average of $40.28 and a two-hundred day simple moving average of $36.83.
Several institutional investors and hedge funds have recently modified their holdings of RHHBY. MAI Capital Management boosted its position in shares of Roche Holdings AG Basel by 27.6% during the 2nd quarter. MAI Capital Management now owns 8,171 shares of the company’s stock valued at $287,000 after acquiring an additional 1,768 shares during the last quarter. Colony Group LLC bought a new stake in Roche Holdings AG Basel in the 2nd quarter worth approximately $6,887,000. Chartwell Investment Partners LLC lifted its position in Roche Holdings AG Basel by 13.1% in the 2nd quarter. Chartwell Investment Partners LLC now owns 121,825 shares of the company’s stock worth $4,290,000 after buying an additional 14,102 shares during the last quarter. Lenox Wealth Advisors LLC lifted its position in Roche Holdings AG Basel by 227.6% in the 3rd quarter. Lenox Wealth Advisors LLC now owns 1,127 shares of the company’s stock worth $41,000 after buying an additional 783 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC lifted its position in Roche Holdings AG Basel by 19.8% in the 3rd quarter. Douglass Winthrop Advisors LLC now owns 764,226 shares of the company’s stock worth $27,856,000 after buying an additional 126,248 shares during the last quarter. Hedge funds and other institutional investors own 0.32% of the company’s stock.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Recommended Story: Percentage Gainers
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.